Evidence map›Paper›PMID 31792736›Full record

ArticleJournal of gastrointestinal cancer2020

Racial Diversity in Hepatocellular Carcinoma in a Predominately African-American Population at an Urban Medical Center.

Brian Rutledge, Jenny Jan, Sindhuri Benjaram, Neha Sahni, Paul Naylor, Philip Philip, Murray Ehrinpreis, Milton Mutchnick

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Brian RutledgeDepartment of Gastroenterology, Wayne State University School of Medicine, 3990 John R St 6 Hudson Room 6938, Detroit, MI, 48201, USA. drbrianrutledge@gmail.com.ORCID http://orcid.org/0000-0002-4766-909X
Jenny JanDepartment of Gastroenterology, Wayne State University School of Medicine, 3990 John R St 6 Hudson Room 6938, Detroit, MI, 48201, USA.
Sindhuri BenjaramDepartment of Gastroenterology, Wayne State University School of Medicine, 3990 John R St 6 Hudson Room 6938, Detroit, MI, 48201, USA.
Neha SahniDepartment of Gastroenterology, Wayne State University School of Medicine, 3990 John R St 6 Hudson Room 6938, Detroit, MI, 48201, USA.
Paul NaylorDepartment of Gastroenterology, Wayne State University School of Medicine, 3990 John R St 6 Hudson Room 6938, Detroit, MI, 48201, USA.
Philip PhilipDepartment of Oncology, Karmanos Cancer Institute/Wayne State University School of Medicine, Detroit, MI, USA.
Murray EhrinpreisDepartment of Gastroenterology, Wayne State University School of Medicine, 3990 John R St 6 Hudson Room 6938, Detroit, MI, 48201, USA.
Milton MutchnickDepartment of Gastroenterology, Wayne State University School of Medicine, 3990 John R St 6 Hudson Room 6938, Detroit, MI, 48201, USA.
Wayne State University · US

Funding

Gilead Sciences IN-US-334-1749
6 · The paper itself

Abstract

purposeSurveillance, treatment, and outcomes for African-American (AA) populations with hepatocellular carcinoma (HCC) remain under evaluated. This study evaluated demographics, surveillance, therapy, and outcomes for a predominately AA population.

methodsThe electronic medical records of a large health-care provider were used to identify 274 patients with visits for HCC between 2010 and 2017. Tumor size at diagnosis was defined by imaging with ≤ 5 cm being defined as "small." Surveillance for HCC was defined based on ultrasound (US) assessments.

resultsPatients were primarily AA (78%) and male (76%) with an average age at diagnosis of 62 years. Hepatitis C virus (HCV) was more likely to be a risk factor for the development of HCC in AA as compared to non-AA (92% vs 67%; p < 0.005). Surveillance rates were low (16% for AA vs 7% for non-AA). An aspartate aminotransferase platelet ratio index (APRI) value > 0.7 within 2 years of tumor diagnosis was a strong predictor for the risk of the development of HCC (86% AA vs 79 % non-AA). In this study, race was not a factor in treatment or outcomes, and most patients received tumor ablative treatment.

conclusionGiven the low surveillance rates and the demonstrated increased survival for patients with small tumors, ways to increase surveillance must be initiated. The results of this study demonstrate the need for physician/patient education on the importance of surveillance US. Further, this study supports routine assessment of APRI in AA patients in an effort to identify patients in whom intensive surveillance will significantly improve earlier detection of tumors.

Indexed as

Healthcare DisparitiesBlack or African AmericanCarcinoma, HepatocellularCombined Modality TherapyEthnicityFemaleFollow-Up StudiesHumansLiver NeoplasmsMaleMiddle AgedPrognosisRisk FactorsSurvival RateAfrican-AmericanHepatocellular carcinomaUltrasound (US)

Identifiers

PMID31792736
OpenAlexW2994199226

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.